According to researchers, Zolgensma, made by Novartis, will lead the global spinal muscular atrophy market and generate billions in sales.
List view / Grid view
Filter the results
The FDA has approved Isturisa for Cushing’s disease treatment after it demonstrated significant efficacy in clinical trials.
The FDA and EMA have accepted licence applications for ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS).
An external review of the medicine Beovu has been announced by Novartis, which produces the drug, according to a new report.
The US Food and Drug Administration (FDA) has granted Priority Review for capmatinib, a treatment for MET exon 14 skipping mutated non-small cell lung cancer.
A new report has revealed Johnson & Johnson as the most valuable pharmaceutical brand, despite a decrease in profits from last year.
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
A partnership between Novartis and NHS England includes a proposal to investigate processes that can increase the scale and efficacy of oligonucleotide manufacture.
Research has found that the top five pharmaceutical companies averaged a Market Capitalisation decline of five percent in Q3 of 2019.
Novartis, Merck and Allergan have joined numerous other pharmaceutical companies by increasing the price of certain drugs since the start of 2020.
Top pharmaceutical companies have reduced their drug costs in China by an average of 61 percent, to be added to the reimbursement list in the country.
The M&A between Novartis and The Medicines Company will add inclisiran, the potentially first-in-class treatment to reduce cholesterol, to the former’s pipeline.
The first Pharmaceutical Invention Index, which looks at the breadth and depth of novel agents currently being developed within the most innovative pharma pipelines, has been released.